It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors’ radar screens for a reason, though there are some hidden gems that could be worth uncovering by those with a high risk tolerance.
One way to find these underappreciated stocks is by looking at companies that haven’t seen their share prices move higher lately, but have observed analysts raising earnings estimates for their stock. This trend could signal that investors haven’t quite embraced the rising estimate story yet, but that the potential for a big move higher is definitely there.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Autoliv, Inc. (ALV - Free Report) . This Automotive - Original Equipment stock has actually seen estimates rise over the past month for the current fiscal year by about 15.6%. But that is not yet reflected in its price, as the stock lost 34.1% over the same time frame.
Autoliv, Inc. Price and Consensus
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 28.7%, which should ultimately translate into price appreciation.
And if this isn’t enough, ALV currently carries a Zacks Rank #1 (Strong Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance). You can see the complete list of today’s Zacks #1 Rank stocks here.
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Autoliv. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for ALV and that now might be an interesting buying opportunity.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>